A growing number of companies have launched clinical trials for methyl​enedioxy​methamphetamine (MDMA) and its derivatives. The most recent is Atai Life Sciences, which saw its share price surge 7.71% in mid-day trading to $3.38 after announcing it had launched a Phase 1 study of an MDMA derivative, EMP-01. The study will focus on post-traumatic stress…